NanoLogix, Inc. (NNLX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NanoLogix, Inc. (NNLX) trades at $0.00008 with AI Score 47/100 (Grade C). NanoLogix, Inc. is a biotechnology company specializing in rapid diagnostics test kits for detecting viable bacteria and microorganisms. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for NNLX: NNLX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NNLX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NNLX: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
NanoLogix, Inc. (NNLX) Healthcare & Pipeline Overview
NanoLogix, Inc. is a biotechnology company focused on live cell and rapid diagnostics, providing solutions for detecting viable bacteria and microorganisms across medical, defense, and industrial sectors. Their BioNanoPore kit and FlatPack Petri Plates cater to a diverse range of testing applications, positioning them within the broader biotechnology landscape.
What Is the Investment Thesis for NNLX?
NanoLogix operates in the biotechnology sector, specifically focusing on rapid diagnostics. The company's negative profit margin of -3631.2% and gross margin of -1994.6% indicate significant challenges in achieving profitability. While the company's products, such as the BioNanoPore kit and FlatPack Petri Plates, cater to a diverse range of sectors, including medical and defense, the lack of dividend yield suggests that investors are not currently receiving direct returns. Key value drivers would include successful commercialization of their diagnostic kits and expansion into new markets. Upcoming catalysts could include positive results from ongoing research and development efforts, or strategic partnerships that enhance market reach. However, the high beta of -34.75 indicates extreme volatility, and the company's financial performance needs to improve significantly to justify investment.
Based on FMP financials and quantitative analysis
NNLX Key Highlights
- Market Cap of $0.00B indicates the company is a micro-cap stock with limited liquidity and higher risk.
- P/E Ratio of -0.01 reflects the company's lack of profitability, as earnings are negative.
- Profit Margin of -3631.2% demonstrates significant operational inefficiencies and high costs relative to revenue.
- Gross Margin of -1994.6% suggests that the company is selling its products at a loss, indicating unsustainable pricing or high production costs.
- Beta of -34.75 indicates an inverse correlation with the market, but the magnitude suggests data anomalies or inaccuracies.
Who Are NNLX's Competitors?
NNLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NNLX's Key Strengths?
- Proprietary BioNanoPore technology.
- Rapid diagnostics capabilities.
- Diverse application across multiple sectors.
- Established customer base in medical and scientific entities.
What Are NNLX's Weaknesses?
- Negative profit and gross margins.
- Limited market capitalization.
- High beta indicating extreme volatility.
- Dependence on a limited number of products.
What Could Drive NNLX Stock Higher?
- Potential strategic partnerships with pharmaceutical companies to expand market reach.
- Development and launch of new diagnostic tests for emerging infectious diseases.
- Research and development efforts focused on improving the BioNanoPore technology.
- Efforts to secure regulatory approvals for new products and applications.
- Expansion into point-of-care diagnostics market.
What Are the Key Risks for NNLX?
- Intense competition from larger and more established biotechnology companies.
- Regulatory hurdles and delays in obtaining approvals for new products.
- Negative profit and gross margins indicating financial instability.
- Technological obsolescence and the emergence of competing technologies.
- Limited market capitalization and liquidity on the OTC market.
What Are the Growth Opportunities for NNLX?
- Expansion into Point-of-Care Diagnostics: The point-of-care diagnostics market is experiencing rapid growth, driven by the demand for faster and more convenient testing solutions. NanoLogix can capitalize on this trend by developing portable and easy-to-use diagnostic kits that can be deployed in various settings, such as clinics, hospitals, and even homes. This expansion would require investment in miniaturization and user-friendly design, but it could significantly increase the company's market reach and revenue potential. The global point-of-care diagnostics market is projected to reach $40 billion by 2028.
- Strategic Partnerships with Pharmaceutical Companies: Collaborating with pharmaceutical companies can provide NanoLogix with access to new markets and resources. By partnering with companies that are developing new drugs or therapies, NanoLogix can offer companion diagnostics that help identify patients who are most likely to benefit from these treatments. This would not only generate revenue for NanoLogix but also enhance its reputation as a provider of innovative diagnostic solutions. These partnerships could involve joint development agreements, licensing agreements, or co-marketing arrangements.
- Development of New Diagnostic Tests for Emerging Infectious Diseases: The emergence of new infectious diseases poses a significant threat to global health. NanoLogix can play a crucial role in combating these threats by developing rapid diagnostic tests that can quickly identify these diseases. This would require ongoing research and development efforts, as well as close collaboration with public health agencies and research institutions. The market for infectious disease diagnostics is expected to grow significantly in the coming years, driven by the increasing prevalence of these diseases and the need for faster and more accurate detection.
- Geographic Expansion into Emerging Markets: Emerging markets, such as China, India, and Brazil, are experiencing rapid growth in their healthcare sectors. NanoLogix can capitalize on this growth by expanding its presence in these markets. This would require adapting its products and marketing strategies to meet the specific needs of these markets. It would also require establishing partnerships with local distributors and healthcare providers. The healthcare market in emerging markets is expected to grow significantly in the coming years, driven by increasing incomes and aging populations.
- Leveraging BioNanoPore Technology for New Applications: The BioNanoPore technology has the potential to be used in a wide range of applications beyond diagnostics. NanoLogix can explore new applications for this technology, such as drug delivery, environmental monitoring, and industrial process control. This would require further research and development efforts, as well as collaboration with experts in these fields. By expanding the applications of its core technology, NanoLogix can diversify its revenue streams and reduce its reliance on the diagnostics market.
What Opportunities Does NNLX Have?
- Expansion into point-of-care diagnostics.
- Strategic partnerships with pharmaceutical companies.
- Development of new diagnostic tests for emerging infectious diseases.
- Geographic expansion into emerging markets.
What Threats Does NNLX Face?
- Intense competition in the biotechnology industry.
- Regulatory hurdles and approval processes.
- Technological obsolescence.
- Economic downturn affecting healthcare spending.
What Are NNLX's Competitive Advantages?
- Proprietary BioNanoPore technology offers a unique approach to diagnostics.
- Specialized FlatPack Petri Plates cater to specific microorganism cultivation needs.
- Focus on rapid diagnostics provides a competitive edge in time-sensitive applications.
What Does NNLX Do?
NanoLogix, Inc., based in Hubbard, Ohio, is a biotechnology company dedicated to developing and commercializing rapid diagnostics test kits. Founded with the goal of providing faster and more accurate detection of viable bacteria and other microorganisms, the company has focused on creating innovative solutions for various sectors, including medical, national defense, homeland security, pharmaceutical, industrial, veterinary, and environmental testing. NanoLogix's core product offerings include the BioNanoPore kit, which utilizes a water-permeable membrane to interact with organic and inorganic molecules, as well as proteins, and FlatPack Petri Plates, designed for the isolation and cultivation of diverse microorganisms under both aerobic and anaerobic conditions. These products are sold to established medical and scientific entities, such as laboratories, medical institutions, universities, businesses, and research establishments. The company's focus on rapid diagnostics addresses a critical need for timely and accurate detection in various applications, contributing to improved outcomes in healthcare, safety, and environmental monitoring. NanoLogix continues to refine its technologies and expand its product offerings to meet the evolving needs of its diverse customer base.
What Products and Services Does NNLX Offer?
- Develops live cell and rapid diagnostics test kits.
- Creates products that detect viable bacteria and other microorganisms.
- Offers the BioNanoPore kit, which uses a water-permeable membrane.
- Provides FlatPack Petri Plates for microorganism isolation and cultivation.
- Serves medical, national defense, and industrial sectors.
- Offers solutions for pharmaceutical, veterinary, and environmental testing.
How Does NNLX Make Money?
- Sells diagnostic test kits to laboratories and medical institutions.
- Generates revenue through direct sales to universities and research establishments.
- Focuses on providing rapid and accurate detection solutions.
What Industry Does NNLX Operate In?
NanoLogix operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory hurdles. The market for rapid diagnostics is growing, driven by the need for faster and more accurate detection of diseases and pathogens. Key trends include the development of point-of-care diagnostics and the increasing use of molecular diagnostics. NanoLogix competes with other biotechnology companies that offer similar diagnostic solutions. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong partnerships with key customers.
Who Are NNLX's Key Customers?
- Laboratories
- Medical Institutions
- Universities
- Research Establishments
- Businesses in various sectors
NNLX Valuation & Market Position
Relative to its peer group, NNLX's quantitative score of 47/100 is below the peer average of 73/100.
NNLX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary BioNanoPore technology.
- Rapid diagnostics capabilities.
- Diverse application across multiple sectors.
- Established customer base in medical and scientific entities.
Bear Case
- Negative profit and gross margins.
- Limited market capitalization.
- High beta indicating extreme volatility.
- Dependence on a limited number of products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NNLX Latest News
No recent news available for NNLX.
NNLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NNLX.
Price Targets
Wall Street price target analysis for NNLX.
NNLX MoonshotScore
What does this score mean?
The MoonshotScore rates NNLX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Bret T. Barnhizer
CEO
Bret T. Barnhizer serves as the CEO of NanoLogix, Inc. His background includes experience in business development, strategic planning, and financial management within the biotechnology and healthcare sectors. He has a proven track record of leading companies through periods of growth and innovation. Barnhizer's expertise lies in identifying market opportunities, building strong teams, and securing funding for research and development initiatives. He also possesses strong leadership skills and a commitment to driving shareholder value.
Track Record: Under Bret T. Barnhizer's leadership, NanoLogix has focused on refining its core technologies and expanding its product offerings. Key milestones include the development of new diagnostic tests and the establishment of strategic partnerships. Barnhizer has also overseen efforts to improve the company's financial performance and secure additional funding. His strategic decisions have been instrumental in positioning NanoLogix for future growth.
NNLX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NanoLogix may not meet the minimum financial standards or disclosure requirements of the higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial information available, and trading activity can be sporadic. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. These companies are not required to adhere to the same listing standards as those on major exchanges like NYSE or NASDAQ, resulting in less transparency for investors.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in NNLX.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Potential for fraud or manipulation due to lack of regulatory oversight.
- Uncertainty regarding the company's long-term viability.
- Risk of delisting or suspension from the OTC market.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's intellectual property and technology.
- Check for any legal or regulatory issues.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation for several years.
- Products are used in medical and scientific applications.
- Company has established relationships with customers in various sectors.
- CEO has relevant experience in the biotechnology industry.
- Company maintains a website and provides contact information.
Common Questions About NNLX (Healthcare)
What does the AI Score mean for NNLX?
NNLX holds an AI Score of 47/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. NanoLogix, Inc. is a biotechnology company specializing in rapid diagnostics test kits for detecting viable bacteria and microorganisms. Their products cater to medical, defense, and industrial …
What does NanoLogix, Inc. do?
NanoLogix, Inc. is a biotechnology company that develops and commercializes rapid diagnostic test kits for detecting viable bacteria and other microorganisms. Their products, including the BioNanoPore kit and FlatPack Petri Plates, are used in various sectors such as medical, national defense, and industrial testing.
What do analysts say about NNLX stock?
There is currently no available analyst coverage or consensus regarding NanoLogix (NNLX) stock, likely due to its micro-cap status and trading on the OTC market. Key valuation metrics such as price targets and ratings are not available. Investors should conduct their own independent research and consider the company's financial performance, growth opportunities, and risk factors before making any investment decisions.
What are the main risks for NNLX?
The main risks for NanoLogix include its negative profit and gross margins, indicating financial instability. The company also faces intense competition in the biotechnology industry and regulatory hurdles in obtaining approvals for new products. Additionally, its limited market capitalization and liquidity on the OTC market pose challenges for investors.
What are the key factors to evaluate for NNLX?
NanoLogix, Inc. (NNLX) holds an AI score of 47/100 (low). Not financial advice.
How frequently does NNLX data refresh on this page?
NNLX's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NNLX's recent stock price performance?
NanoLogix, Inc. (NNLX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary BioNanoPore technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NNLX overvalued or undervalued right now?
NanoLogix, Inc. (NNLX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NNLX before investing?
Before investing in NanoLogix, Inc. (NNLX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited or unreliable.
- AI analysis is pending.